Organon To Present Results Of Post-Hoc Sub-Analysis Of Pooled Data From Phase 3 ADORING 1 And ADORING 2 Pivotal Trials Evaluating Efficacy And Safety Of VTAMA Cream Versus Vehicle At AAD Annual Meeting
VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak Pruritus-Numeric Rating Scale (PP-NRS) with results seen as early as week 1, and continued through week 8
Statistically significant ≥75% improvement in Eczema Area and Severity Index (EASI75) response was achieved as early as week 1 and continued through week 8
Improvements in Eczema Area and Severity Index (EASI) scores were achieved by the majority of patients (96.9%) from baseline at week 8
Login to comment